SCHEMBL7449090

SCHEMBL7449090

Cn1ncc(N)c1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
HTT P42858 2/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
MAPT P10636 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
KDM6B O15054 1/20 0.34
KDM4A O75164 1/20 0.34
THRB P10828 1/20 0.34
KDM4D Q6B0I6 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2099625 0.83 ALDH1A1 (0.42) HTTL3MBTL1MAPTALDH1A1KDM4E
SCHEMBL1432563 0.79 HTT (0.43) KMT2AHTTL3MBTL1MAPTTDP1
SCHEMBL1876572 0.79 CNR2 (0.46) KMT2AHTTALDH1A1KDM4EMEN1
SCHEMBL7461101 0.79 HTT (0.42) HTTMAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL7511119 0.79 LMNA (0.38) KMT2AHTTMAPTALDH1A1SMN1; SMN2
SCHEMBL24611908 0.79 KMT2A (0.36) KMT2AHTTL3MBTL1MAPTALDH1A1
SCHEMBL68535 0.77 PDE10A (0.41) KMT2AHTTL3MBTL1MAPTTDP1
SCHEMBL2212203 0.77 L3MBTL1 (0.39) KMT2AHTTL3MBTL1MAPTTDP1
SCHEMBL1458362 0.76 RIPK2 (0.41) KMT2AHTTMAPTTDP1ALDH1A1
SCHEMBL1357879 0.75 HTT (0.50) HTTL3MBTL1POLBSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof TERREMOTO BIOSCIENCES, INC. (US) 2026-03-10 US disclosed
WO-2025081045-A9 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-12-26 WO disclosed
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 US disclosed
WO-2025081045-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-04-17 WO disclosed
US-20240368114-A1 INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX INC (US) 2024-11-07 US disclosed
CN-117355524-A Pharmaceutically acceptable salt of pyrazoloheteroaryl derivative and crystal form thereof 江苏恒瑞医药股份有限公司 2024-01-05 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20220169634-A1 AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF BIOARDIS LLC 2022-06-02 US disclosed
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP disclosed
US-9604977-B2 Bicyclic thiophenylamide compounds HOFFMAN-LA ROCHE INC. (US) 2017-03-28 US disclosed
EP-2861574-B1 NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS HOFFMANN LA ROCHE (CH) 2016-04-20 EP disclosed
US-20150175594-A1 NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2015-06-25 US disclosed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP disclosed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169634-A1 AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF FGFR4, FGFR3, FGFR1 KMT2A 1666/4885HTT 2510/4885L3MBTL1 3857/4885
US-20240368114-A1 INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1G3, CSNK1A1, CSNK1D KMT2A 3224/4885HTT 4026/4885L3MBTL1 3588/4885
US-20150175594-A1 NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS NAT1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BICRA KMT2A 1633/4885HTT 1582/4885L3MBTL1 1920/4885
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof AKT1, AKT2, AKT3 KMT2A 1229/4885HTT 3562/4885L3MBTL1 2110/4885
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT2, AKT3 KMT2A 932/4885HTT 2987/4885L3MBTL1 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.